Cargando…

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

OBJECTIVE: To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA). METHODS: Patients were randomized 1:1 in a double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genovese, Mark C., Glover, Josephine, Greenwald, Maria, Porawska, Wieslawa, El Khouri, Elias Chalouhi, Dokoupilova, Eva, Vargas, Juan Ignacio, Stanislavchuk, Mykola, Kellner, Herbert, Baranova, Elena, Matsunaga, Nobuhito, Alten, Rieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909638/ https://www.ncbi.nlm.nih.gov/pubmed/31831079 http://dx.doi.org/10.1186/s13075-019-2046-0

Ejemplares similares

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
por: Schreiber, Stefan, et al.
Publicado: (2020)

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
por: Genovese, Mark C, et al.
Publicado: (2020)

Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants
por: Yonemura, Takuma, et al.
Publicado: (2022)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

HSP-90/kinase complexes are stabilized by the large PPIase FKB-6
por: Sima, Siyuan, et al.
Publicado: (2021)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2022)

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Regulating chromosomal movement by the cochaperone FKB-6 ensures timely pairing and synapsis
por: Alleva, Benjamin, et al.
Publicado: (2017)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Structural characterization of PaFkbA: A periplasmic chaperone from Pseudomonas aeruginosa
por: Huang, Qin, et al.
Publicado: (2021)

Health Tract No. 327: The Pulse
Publicado: (1868)

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
por: Liu, Jennifer, et al.
Publicado: (2016)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects
por: Bush, Jim, et al.
Publicado: (2019)

Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions
por: Lindemann, Carsten, et al.
Publicado: (2013)

Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome
por: Sota, Jurgen, et al.
Publicado: (2021)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_085uecfvs29jtqsnmsik3l0931